Skip to main content Accessibility help
×
×
Home

Information:

  • Access
  • Cited by 4
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Valencia, M. Fresan, A. Juárez, F. Escamilla, R. and Saracco, R. 2013. The beneficial effects of combining pharmacological and psychosocial treatment on remission and functional outcome in outpatients with schizophrenia. Journal of Psychiatric Research, Vol. 47, Issue. 12, p. 1886.

    Wciórka, Jacek Świtaj, Piotr and Anczewska, Marta 2015. The stages of recovery in relation to the other subjective and objective aspects of psychosis. Psychiatry Research, Vol. 225, Issue. 3, p. 613.

    Jones, Rose Major, Barnaby and Fear, Christopher 2015. Schizophrenia in a Primary Care Setting. Current Psychiatry Reports, Vol. 17, Issue. 10,

    Rae, Charlotte L. Davies, Geoff Garfinkel, Sarah N. Gabel, Matt C. Dowell, Nicholas G. Cercignani, Mara Seth, Anil K. Greenwood, Kathryn E. Medford, Nick and Critchley, Hugo D. 2017. Deficits in Neurite Density Underlie White Matter Structure Abnormalities in First-Episode Psychosis. Biological Psychiatry, Vol. 82, Issue. 10, p. 716.

    ×

Figures:

Actions:

      • Send article to Kindle

        To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

        Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

        Find out more about the Kindle Personal Document Service.

        Resolution and remission in schizophrenia: getting well and staying well
        Available formats
        ×

        Send article to Dropbox

        To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

        Resolution and remission in schizophrenia: getting well and staying well
        Available formats
        ×

        Send article to Google Drive

        To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

        Resolution and remission in schizophrenia: getting well and staying well
        Available formats
        ×
Export citation

Summary

Remission is a new research outcome indicating long-term wellness. Remission not only sets a standard for minimal severity of symptoms and signs (resolution); it also sets a standard for how long symptoms and signs need to remain at this minimal level (6 months). Individuals who achieve remission from schizophrenia have better subjective well-being and better functional outcomes than those who do not. Research suggests that remission can be achieved in 20–60% of people with schizophrenia. There is some evidence of the usefulness of remission as an outcome indicator for clinicians, service users and their carers. This article reviews the literature on remission in schizophrenia and asks whether it could be a useful clinical standard of well-being and a foundation for functional improvement and recovery.

Footnotes

Declaration of Interest

The authors met to discuss the remission concept at a meeting supported by Janssen-Cilag Ltd.

Schizophrenia is a long-term condition. Many people continue to experience residual symptoms after the first episode. Some suffer relapses, or remain ill and functionally impaired (Robinson 2004). Any outcome measure for schizophrenia needs to be capable of delivering a meaningful assessment of an individual's experience across their lifespan as well as in the short term; episodic outcome measures may miss the long-term cumulative effects of schizophrenia. Outcome measures must be capable of informing clinical decision-making. They should contribute to reviews and care-planning. New recovery measures show promise, but they do not generally measure symptomatic improvement over the short and medium time scales involved in a hospital admission and immediate aftercare.

Outcome measures should provide healthcare funders with information about the effectiveness of interventions and services. For clinicians they should be quick and easy to use and have a solid evidence base. The outcomes themselves should be meaningful to mental health service users and their families. A single measure that satisfies all these stakeholders would be ideal.

A survey of 340 UK psychiatrists revealed a low rate of routine use of outcome measures and a general attitude that such measures are not useful. Its authors concluded: ‘Outcomes measurement is a “technology” that has opportunity costs and therefore must be shown to be beneficial in improving the quality of care as measured by actual outcomes of patients or communities. No direct evidence exists that there is a benefit in this respect for those working and being cared for in either primary care or specialist psychiatric services’ (Gilbody 2002).

Since the early 1990s, policy makers in the UK have taken an increasing interest in outcome measures and services are encouraged to introduce them (Department of Health 2005). However, the statement above may still be accurate. Clinicians may not be convinced that measuring outcomes improves patient care and may feel that the time taken to perform measurement is time that could be better used delivering that care.

Resolution and remission in schizophrenia

A good approach to studying the outcome of schizophrenia is to measure the disappearance or resolution of symptoms and signs (Peuskens 2007). If someone who has had schizophrenia no longer has symptoms and signs then they are better. This is familiar territory for mental health professionals. Resolution of symptoms is often seen as the primary endpoint of acute interventions such as hospital admission or medication treatment. Yet this resolution of symptoms is a momentary achievement. For many people, it does not last (Robinson 2004). A lasting resolution of symptoms and signs is called a remission (Box 1). A person with schizophrenia in remission is clinically well. If this clinical outcome correlates with subjective well-being then it could be meaningful to patients. As we shall see below, schizophrenia sufferers in remission do better than those who achieve only brief symptom resolution (Box 2).

BOX 1 Resolution and remission

Resolution Remission
Symptomatic requirement Minimal symptoms below a set threshold on all symptom domains Minimal symptoms below a set threshold on all symptom domains
Time requirement No time specified Lasting at least 6 months

BOX 2 Reported benefits of remission over resolution

  1. Better quality of life

  2. Longer time symptom free

  3. Positive attitude to medication

  4. Lower doses of medication

  5. Fewer extrapyramidal symptoms

  6. Better global function

  7. Better insight

Standardised remission criteria: a Consensus Group solution

A research standard for remission in schizophrenia was described in 2005 by a Consensus Group led by Andreasen et al. This group included international experts and reached a consensus on a definition of remission that had two components (Andreasen 2005).

The severity component: resolution

The first component was a measure of the severity of symptoms and signs (i.e. resolution). For this component they chose a well-used, validated scale, the Positive and Negative Syndrome Scale (PANSS) (Kay 1987). Recognising a certain amount of redundancy in the full PANSS, they extracted eight PANSS items to represent three core domains of schizophrenia: positive symptoms, negative symptoms and disorganisation of thinking and behaviour (Box 3). Each item is defined within the PANSS and correlates very much with what most psychiatrists would expect by the terms used. For example, ‘hallucinatory behaviour’ refers to verbal report or behaviour indicating perceptions that are not generated by external stimuli. ‘Unusual thought content’ refers to strange, fantastic or bizarre ideas that are not necessarily delusional. Each item is rated separately on a scale of 1 to 7, with 7 the most severe rating. The group recommended that, to meet the severity criterion of remission, each of the eight items should score 3 or less (see Box 4): no symptom or sign should be rated more than mild.

BOX 3 The eight PANSS symptoms and signs used to rate remission

Symptoms and signs Domain
Delusions Positive symptom
Unusual thought content Positive symptom
Hallucinatory behaviour Positive symptom
Conceptual disorganisation Disorganisation
Mannerisms/posturing Disorganisation
Blunted affect Negative symptom
Social withdrawal Negative symptom
Lack of spontaneity Negative symptom
(Andreasen 2005)

BOX 4 Generic rating guide for PANSS symptoms

Rating level For all symptoms and signs
1 Absent Absent
2 Minimal Questionable pathology, extreme normal limits
3 Mild Symptoms are clearly present but vague and relatively unobtrusive. They do not interfere with thinking, social relations or behaviour
4 Moderate Symptoms are several and unquestionable but shifting and only occasionally interfere with thinking, social relations and behaviour
5 Moderately severe Symptoms clearly manifest and preoccupy patient, occasionally interfere with thinking, social relations and behaviour
6 Severe Symptoms extensive and manifest, preoccupy patient and clearly interfere with thinking, social relations and behaviour
7 Extreme Symptoms are severe and extensive and dominate major facets of life, leading to often inappropriate, irresponsible actions

The original PANSS has specific rating criteria for each symptom or sign. Basic PANSS training can be completed in a single day. For those with less time, we have condensed the eight specific ratings into a generic rating system for ease of use in clinical settings (Box 4). Delusions rated on the original PANSS scale at severity grade 3 would have the following characteristics: ‘One or two delusions, which are vague, un-crystallized and not tenaciously held. Delusions do not interfere with thinking, social relations or behaviour’ (Kay 1987). On our generic rating system this becomes: ‘Symptoms are clearly present but vague and relatively unobtrusive. They do not interfere with thinking, social relations or behaviour’.

The time component: remission

The Consensus Group importantly put forward a second component of remission. This is a time component. The group wanted to move away from easily achieved targets of brief symptom reduction to a more demanding goal of prolonged wellness. They recommend that for remission to be considered achieved, all eight symptoms and signs should rate 3 or less for a period of 6 months.

Evaluation of the Consensus Group criteria

In their review of the Consensus Group's definition of remission, van Os et al (2006) felt that the remission concept would be useful for clinical trials and could be easily used in clinical practice. They suggested that using the concept would increase expectations of treatment and facilitate discussions about treatment objectives. They hoped that the remission concept might inform decisions about discharge from hospital, but thought that the 6-month criterion for remission would make it difficult to facilitate service-level decisions in fast-moving clinical services. However, they considered the severity component of the definition (resolution) valuable in assessing readiness for discharge.

Clinical Global Impression–Schizophrenia scale

Another proposed measure of remission is the Clinical Global Impression–Schizophrenia (CGI–SCH) scale (Haro 2003). It is very brief and relies on the clinical impressions of the rater. It covers the domains of positive and negative symptoms and cognition. It also adds the domains of depression and of overall severity of illness. The CGI–SCH scale can be rated serially over time but it also allows the rater to use a ‘change’ scale for each domain instead of using serial measurements. This means that the rater can make an estimate of how much a patient's symptoms have changed at a single clinical contact. To mark remission, the authors suggest using the same cut off of 3 or less (mildly, minimally or not ill) on their 7-point scales (1, not ill; 7, among the most severely ill) on each of the positive, negative, cognitive and overall severity scales (Haro 2007). They do not require a particular period of time to have elapsed before remission status is considered to have been achieved. Therefore their definition is a measure of symptom resolution and is different from the standard required by the Consensus Group (Andreasen 2005). It is of course simple to add the 6-month criterion to make CGI–SCH remission comparable to the Consensus Group definition.

Summary of research

The literature investigating the concept of remission is growing. Studies have addressed both the severity component of the concept (resolution) and full remission with the important 6-month duration component. Several studies have compared patients achieving resolution with patients who maintain resolution for 6 months and achieve remission. One naturalistic cohort study examined the symptom severity component and the duration component of the remission criteria separately (De Hert 2007). Of the 341 Belgian participants involved, all of whom had schizophrenia or schizoaffective disorder, those who initially met just the severity criterion (resolution) had a poorer outcome at endpoint than those who had also met the 6-month duration criterion (remission). Those in remission had higher global function, fewer symptoms and better insight into illness at endpoint. In first-episode schizophrenia as well, remission is associated with better symptomatic and functional outcomes than non-remission (Wunderink 2007; Addington 2008).

Symptom resolution proceeds to remission in many patients. In the naturalistic cohort study just discussed (De Hert 2007), 21% of the patients who had not met remission criteria at baseline achieved remission on treatment within a year. Another 1-year study, of long-acting risperidone injection for schizophrenia or schizoaffective disorder, found that two-thirds of the 578 clinically stable patients considered to be well were not in remission at baseline (Lasser 2005). With risperidone treatment, one-fifth of those non-remitted at baseline felt that their health had improved and achieved remission for at least 6 months. This suggests that systematic enquiry into mental state reveals treatable residual symptoms for a significant number of patients.

Remission was also investigated as part of a retrospective observational study (the European Schizophrenia Outpatient Health Outcomes – SOHO) in Germany (Lambert 2008a). Untreated patients with recent first episodes of clinically defined schizophrenia were included and followed for up to 3 years while receiving standard clinical care. Outcomes were measured using the CGI–SCH scale (Haro 2003). At baseline 6% of patients were in remission and at endpoint 60% were.

The importance of the time component of remission was demonstrated in a large study of medication treatment of 462 individuals with first-episode psychosis over 2–4 years (Emsley 2007). During the study, 323 (70%) participants achieved resolution according to the severity criteria and 109 (24%) maintained this status for 6 months, reaching remission. The best predictors of reaching remission were shorter duration of untreated psychosis and treatment response at 6 weeks. Patients in remission, in comparison with non-remitters, reported better quality of life, fewer relapses, a more positive attitude to medication and fewer extrapyramidal side-effects. They also received lower doses of medication. The two groups did not differ on composite cognitive scores.

The research to date shows that one of the key uses of remission assessment is to reveal patients with residual symptoms. From all the studies with controlled and naturalistic samples that we found in the literature, 20–60% of stable but unremitted patients can achieve remission with treatment. In the controlled research samples, 75–80% of patients do not proceed from resolution to remission. This is a key finding suggesting limitations to current treatment approaches when the high standards of remission are employed. Despite this overall finding, the significant minority (20–25%) who do achieve remission have better symptomatic improvement, better social function and improved quality of life.

This section is summarised in Key points 1.

The usefulness of remission

The above studies suggest that if people who have experienced schizophrenia achieve 6-month remission, their well-being and function advances beyond those of people with shorter symptomatic improvement. If mental health organisations wish to work towards these outcomes, they might consider the use of remission assessment in routine practice. In an ideal world, clinicians and managers would want to use the same measures, and remission is a candidate for such a universal measure.

Using remission assessment in practice

Let's accept for now that a standard remission measure based on the 8-item modified PANSS score is practical. It takes about 5 min to complete using the generic rating guide in Box 4. We can measure whether patients with a diagnosis of schizophrenia are ill (any item scores ≥ 4) or whether they are in resolution (all items ≤ 3) or in remission (all items ≥ 3 for 6 months). Let's assume we can collect the data in an analytical program such as a spreadsheet or database. What can we do with them? We could see how long it takes patients to achieve resolution, the first stage of remission. This is a useful measure for acute services. We could follow this up after discharge by measuring how many people then achieve remission in the community. We could measure how long it is before patients relapse (if they do). These are helpful measures for community services and primary care.

To see which service activities appear to be associated with resolution and remission, a measure of adherence would be helpful. Evidence suggests that treatment adherence is generally lower than we assume (Coldham 2002; Keith 2003). Medical treatment may vary in effectiveness, depending on whether it is given orally or by injection and whether it is supported by good clinical care.

If a service user has a persistent illness, the lack of remission could trigger a treatment review. We might ask our teams, ‘Why is this person not getting well?’ If we expect remission to occur, that could make us more ambitious to help achieve it (Nasrallah 2006). Perhaps more pragmatically, if we notice that remission is slow in coming, we could match that progress to an appropriate treatment stream. Some patients might do better in a stream with more psychosocial work, or more carer support. We could use remission to redirect resources, to give up on ineffective treatment, to reformulate our clinical understanding of service users and to change care plans (Mortimer 2005).

The extent of non-remission and its quality could help us characterise illness experiences using the three symptom domains of positive and negative symptoms and disorganisation. The PANSS scale will show whether negative symptoms are more problematic than positive or disorganised ones and how severe each symptom is. A partial remission with only severe hallucinations could be considered differently from a partial remission with social withdrawal, blunted affect and lack of spontaneity. If we systematically monitor remission then this should help us detect and treat relapses early, as exemplified in the following fictional case study.

Case study

Richard is a 28-year-old man with a diagnosis of schizophrenia since the age of 20 and five hospital admissions for acute psychosis between the ages of 20 and 22. He lives with his parents and has never been able to work. He appears to be asymptomatic for positive symptoms and disorganised thinking but has negative symptoms, including social withdrawal. He has been on depot medication for 6 years. He is unwilling to engage in recovery work. In the course of a remission rating, Richard revealed that he had started hearing a voice several months ago telling him to cut off his fingers to prevent contaminating his parents with evil. A risk assessment concluded that self-harm was likely and he was admitted to hospital to reduce risk and change his care plan. He was able to speak about his concerns to nurses, but remained unwell and apathetic. An alternative depot medication was started, and after 4 weeks Richard reported that the voice had gone and he no longer wanted to cut off his fingers. He no longer thought that he could contaminate anyone with evil. Remission ratings 6 months after discharge confirmed minimal positive and disorganised symptoms but moderately severe negative symptoms. Richard continues to decline all offers of recovery work, but has taken up playing the piano at home. He says he thinks the medication is worthwhile (‘I feel more relaxed’) although he does not think it is connected to the reduction in positive symptoms.

Discussion

Richard had seemed stable for years and reported no positive symptoms in the course of routine contact with the community mental health team. Only on systematic enquiry did he reveal his concerns about hearing a voice, contamination and self-harm. Hospital treatment was associated with a lasting reduction in distress mirrored by the remission assessment for positive symptoms after discharge. The remission assessment also emphasised the extent of persistent negative symptoms. Richard has not achieved resolution or remission, but understanding the nature of the non-remission has led to better treatment outcomes for positive symptoms and established the severity of negative symptoms. The care team is now working to encourage Richard to spend time in a community-based, residential voluntary sector service that is successful at developing independent living and social skills.

Using timelines with remission

If we determine the time, from illness onset, that it takes to achieve remission we get another measure of treatment effectiveness. The faster someone achieves remission the better. Not only do patients suffer fewer traumas from the horrific experiences of psychosis, but services are likely to spend less money on each person, allowing more people to be treated. Services can use resolution and remission to gauge entry to and exit from service components. Discharge from hospital to community services when ill could lead to expensive readmission. Discharge in resolution or remission could lead to better long-term outcomes and fewer relapses. Remission could signal readiness for primary care and voluntary sector services to take an active role in long-term care.

Figure 1 shows a clinical monitoring approach to remission. Four cases are presented as timelines. In the chart, the time component is given priority and is shown on the horizontal axis. Each of the four cases has a very different timeline. Case D has a good outcome: the patient had a short illness with a greater proportion of time (60%) spent in remission. The extended measure of the proportion of time spent in remission since onset of schizophrenia could be the framework in which remission is used as a commissioning standard. It is easy to see that case B has a better outcome than cases A and C. The patient in case C has spent no time in remission in a 10-year period.

It appears likely from the studies conducted so far that subjective wellness and function would mirror extended remission. Clinicians and service funders can audit the difference in outcomes between cases. At 6 years since onset, the patient in case A has had more relapses and achieved 25% of time in remission compared with 75% in case B. Why? If we add treatments and other service inputs to the timeline we could infer how inputs are linked to outcome. We should also consider case-mix, which is the variation in patient presentations: patients with fewer, milder symptoms may achieve remission more easily than those with more severe symptoms and comorbid substance misuse. Treatment adherence should be considered. Failure to progress to full remission could be addressed clinically with step-wise reevaluation and treatment adaptations such as those described by Lambert et al (2008b).

Figure 2 shows a simple care pathway using remission. For some patients who do not achieve remission, a change in their care plan will enable them to do so. From the evidence base it is certain that some patients would not achieve remission despite care plan changes. This lack of remission does not mean that they cannot recover (Robinson 2004), but the recovery might be better if they had achieved remission (Emsley 2007). Commissioners could ask whether it is more cost-effective to fund approaches that lead to sustained remission into wellness, or repeated high-intensity treatments for recurrent illness.

The usefulness of evaluating resolution and remission is summarised in Key points 2.

Limitations of the remission concept in schizophrenia

In their critique of the concept of remission, Leucht et al (2007) raised technical questions about measuring the time component in clinical trials. They also noted that the CGI–SCH severity score of ‘not more than mild’ appears to be as stringent a measure in researchers' hands as Andreasen's Consensus Group criteria.

Relapse

The issue of the time component is important in judging relapse, but this has not been operationalised for the PANSS. If someone in remission briefly rates 4 on a single PANSS item, is that enough to end the remission? If this were the case, the persistence of remission may be less likely the more often one checks for symptoms. Can remission be assumed to continue if it is not monitored for a year? Should remission only take into account symptoms on the day of assessment or should it also include patient and carer historical reports? A less stringent definition of relapse is that proposed for depression by Frank et al (1991). They defined relapse as a return of symptoms satisfying the full syndrome criteria for an episode. For schizophrenia this requires a period with persistent multiple symptoms. More work needs to be done to clarify a definition of relapse in relation to remission in schizophrenia.

The views of service users, carers and psychiatrists

How do service users and carers view remission? In 2007, a survey sponsored by the pharmaceutical industry found that three-quarters of carers of people with schizophrenia thought that remission is a realistic treatment goal (European Federation of Associations of Families of People with Mental Illness 2007). Service users in another study (Lasser 2005) felt that their health improved when they achieved remission. However, there has not been a study focusing on evaluating the usefulness of remission to service users. Some people may have a concern about the term remission, which is more familiar in connection with cancer treatment.

Critical psychiatrists may view remission as little more than another cog in a system of constructed false knowledge designed to sustain the power of professionals and the pharmaceutical industry (Moncrieff 2007). However, remission judged on the basis of symptoms is quite capable of showing the ineffectiveness as well as the effectiveness of drugs and other interventions. Psychiatrists might be concerned about using a measure that can demonstrate poor outcomes if they believe that this would lead to disinvestment in existing services. However, an alternative view is that poor outcomes could demonstrate the need for services to be improved rather than removed.

It is possible that widespread use of remission could be stigmatising. If patients felt labelled as ‘non-remitters’, they might feel pessimistic about the future. Achieving remission could also be problematic for some service users dependent on social security programmes. Those who achieve remission could lose welfare benefits and without recovery-oriented approaches to establishing employment as the source of income, this may be sufficient reason for some service users to be wary of achieving remission.

Factors linked to remission

We have already considered the problem of non-concordance with treatment plans. If we attribute remission to a treatment that was not taken, we might make a systematic error that over-emphasises the value of treatments. This in turn may encourage over-zealous medical treatment when other approaches might be helpful. It is worth attempting some form of adherence monitoring alongside remission measurement. There are many aspects to symptom resolution and remission. Practitioners cannot assume that clinical improvement is linked only to treatment variables. It would be sensible to keep an open mind about the relative contribution of service user personal strengths, family support, occupational stress, physical illness, substance use and chance events. Clinicians also need to bear in mind that comorbid conditions such as depression can persist and prevent recovery even if schizophrenia remits.

Assessment of remission can be complemented by functional measures. Short scales such as the Global Assessment of Functioning (American Psychiatric Association 1987) and the Social Inclusion Scale (Priebe 2008) are appropriate for this purpose. These scales record factors such as relationships, housing status and employment. Complemented in this way, remission can be part of a measure of recovery.

The main limitations of remission are summarised in Key points 3.

Recovery

Although remission is a valid goal of treatment, it is not always the final goal. This is usually considered to be recovery (Table 1). In some outcome schemes, such as the stages of depression described by Frank et al (1991), recovery is described as the next stage after remission. Thus defined, recovery usually embodies long-term remission and a good functional outcome. Remission is a foundation for this kind of recovery. Robinson et al (2004) have given recovery in schizophrenia an operational definition using the Social Adjustment Scale (Schooler 1979). They found that 5 years after a first episode of schizophrenia or schizoaffective disorder, nearly half of patients had achieved remission for 2 years. Only 14% had also achieved sustained recovery. Another 12% had achieved recovery without full remission. Recovery as a standard is more difficult to achieve than remission.

However, recovery can be conceptualised not as a standard, but as a process of self-discovery and self-management. Recovery is then a journey that does not require symptom abatement as a starting point (Roberts 2004; Schrank 2007). This ‘rediscovery’ of recovery has been criticised by Oyebode (2004) who cautions against using ‘ordinary words [such as recovery] to describe the world in ways totally opposed to the original meaning’. Slade (2009) has resolved this debate by defining two types of recovery. Clinical recovery is defined by practitioners in their professional terms, including symptom resolution and remission and the restoration of social function. Personal recovery is an individual process of changing values and meaning leading to a satisfying way of living with, or after, mental illness. Even if some forms of recovery do not need remission, people who make that journey may travel more easily with fewer symptoms.

UK health policy currently favours a recovery approach to illness and a personalised approach to healthcare. An English Green Paper with the title Independence, Well-being and Choice: Our Vision for the Future of Social Care for Adults in England presents a list of outcomes, the first of which is improved health (Department of Health, 2005: p. 10). In schizophrenia, the remission concept may be a useful way of monitoring improved health.

Using the generic modified PANSS

We have been using the Andreasen Consensus Group remission criteria in clinical practice for some time. We have been able to use the severity component alone (resolution) and in combination with the time component (remission). The generic modified PANSS can be administered in standard clinical settings in about 5 min. It is not an additional task since it measures mental state. A simple record sheet such as that shown in Fig. 3 can collect four ratings at different times. Using this, we can readily identify patients who have unremitted symptoms in any of the core domains of schizophrenia (positive and negative symptoms and disorganisation) and review care plans accordingly. For example, one patient had been reducing antipsychotic medication because of side-effects and began to show prominent negative symptoms. The dose of the antipsychotic was increased a little, which resulted in an improvement in negative symptoms without the return of side-effects.

We have used the ratings collaboratively with patients, sharing the results and discussing with them what to do. The ratings have also shown medical students that a consultation is more than an informal meeting; they demonstrate how symptoms are assessed in a structured manner. The ratings are a memory aid for clinicians, encouraging us to check the core symptom domains at each visit. Our teams have shown interest in measuring remission and this has facilitated discussions of care plans to improve outcomes.

All clinicians and health services have a duty to help patients get well and stay well. Resolution and remission give us a way to monitor these outcomes.

Remission in future

Remission is a promising measure for outcome research (Box 5) (Mortimer 2007). However, it is unclear whether the concept can be transferred into clinical practice, where routine outcome measurement is currently rare. In future, patients and their families should be able to choose services based on meaningful standard outcomes. Services able to demonstrate that they help more people get well and stay well for long periods (remission) should prove popular. Some services have already picked alternative approaches to outcome monitoring. Health professionals need to help decide which measures offer best value. It is unlikely that psychiatrists will be able to avoid all forms of outcome measurement in future. Health policies such as Independence, Well-being and Choice (Department of Health 2005) and Putting People First (HM Government 2007: p. 2) require measures of well-being and rapid recovery. The advantage that resolution and remission have compared with other measures is that they represent wellness as a simple, meaningful and evidence-based outcome in schizophrenia.

BOX 5 Potential benefits of remission

  1. It is a standardised outcome measure

  2. It can be applied swiftly in a clinic setting

  3. It could help to demonstrate good-quality care

  4. It could help demonstrate limitations of care

MCQs

  1. 1 Essential features of remission in schizophrenia as defined by Andreasen et al include:

    1. a treatment adherence

    2. b having a job

    3. c not being an in-patient

    4. d mild symptoms (or better) for 6 months or more

    5. e no side-effects attributable to treatment.

  2. 2 Remission in schizophrenia is not associated with:

    1. a better subjective health

    2. b better insight

    3. c better functioning

    4. d reduced symptoms

    5. e better physical health.

  3. 3 The remission concept would not be improved by:

    1. a considering a definition of relapse

    2. b finding out whether patients value remission

    3. c trialling the remission standard in more clinical settings

    4. d reluctance to measure clinical outcomes

    5. e standardising monitoring intervals.

  4. 4 Remission is:

    1. a a well-evidenced standard

    2. b a continuous measure

    3. c time-consuming to assess

    4. d a measure of change

    5. e adjustable to suit each patient.

  5. 5 Carers are likely to find the following clear and meaningful:

    1. a collecting data that are never analysed

    2. b trying to achieve a high standard of wellness for their relatives/friends

    3. c reducing scores on complicated research rating scales

    4. d not recording outcomes at all

    5. e measures of activity relating to interservice transfers.

MCQ answers

1 2 3 4 5
a f a f a f a t a f
b f b f b f b f b t
c f c f c f c f c f
d t d f d t d f d f
e f e t e f e f e f

TABLE 1 Comparison of resolution, remission and recovery assessments in schizophrenia

Recovery
Resolution as a standard a Remission as a standard a As a standard b As a process c
Focus Symptoms Symptoms and time Functional capacity Person
Time to assess Brief Brief Moderate Lengthy
Involves patient No No Somewhat Yes
Well defined, measurable and comparable Yes Yes Somewhat Not yet

KEY POINTS 1 Research findings on remission

  1. Evidence supports the use of remission as a meaningful measure of outcome in schizophrenia

  2. Predictors of remission in first-episode psychosis:

    1. short duration of untreated psychosis

    2. good clinical response in first 6 weeks

  3. 6 Many apparently stable patients have treatable residual symptoms

  4. 7 Remission is a higher standard of outcome than symptom resolution, and is associated with better function and quality of life

  5. 8 Remission may be important for recovery in some patients

KEY POINTS 2 Usefulness of resolution and remission to managers and commissioners

  1. To monitor the effectiveness of high-intensity and high-cost services

  2. To monitor the effectiveness of community services

  3. To monitor non-remission, so as not to underestimate continuing care needs in chronic schizophrenia

  4. To monitor non-remission as a factor in non-recovery (is being ill preventing recovery?)

  5. To use remission as a commissioning standard, by monitoring the proportion of time spent in remission

KEY POINTS 3 Limitations of remission assessment

  1. Many psychiatrists do not value standardised measurement of outcomes

  2. It is not clear whether remission assessment is valuable to patients

  3. Managers may be unfamiliar with remission or wellness assessment, as a measure of service effectiveness

  4. Relapse has yet to be operationally defined

FIG 1 Time in remission as a proportion of time since onset of schizophrenia.

FIG 2 Clinical pathway using remission in schizophrenia.

FIG 3 This record sheet uses Andreasen's Consensus Group standardised remission criteria (Andreasen 2005).

Acknowledgement

Thanks to Dr Angélica Santiago for her comments on a draft of this article.

References

Addington, J, Addington, D (2008) Symptom remission in first episode patients. Schizophrenia Research 106: 281–5.
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM–III–R). APA.
Andreasen, NC, Carpenter, WT, Kane, JM et al (2005) Remission in schizophrenia: proposed criteria and rationale for consensus. American Journal of Psychiatry 162: 441–9.
Coldham, EL, Addington, J, Addington, D (2002) Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica 106: 286–90.
De Hert, M, van Winkel, R, Wampers, M et al (2007) Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophrenia Research 92: 6873.
Department of Health (2005) Independence, Well-being and Choice: Our Vision for the Future of Social Care for Adults in England. Department of Health.
Emsley, R, Rabinowitz, J, Medori, R et al (2007) Remission in early psychosis. Rates, predictors and clinical and functional outcome correlates. Schizophrenia Research 89: 129–39.
European Federation of Associations of Families of People with Mental Illness (2007) New survey conveys fundamental shift in the perceptions of treatment outcomes in schizophrenia. EUFAMI (http://www.eufami.org/index.php?option=com_pressreleasesnewsdesc&Itemid=135&titleid=68).
Frank, E, Prien, RF, Jarrett, RB et al (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry 48: 851–5.
Gilbody, SM, House, AO, Sheldon, TA (2002) Psychiatrists in the UK do not use outcomes measures. National survey. British Journal of Psychiatry 180: 101–3.
Haro, JM, Kamath, SA, Ochoa, S et al (2003) The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatrica Scandinavica Supplementum 416: 1623.
Haro, JM, Ochoa, S, Gervin, M et al (2007) Assessment of remission in schizophrenia with the CGI and CGI–SCH scales. Acta Psychiatrica Scandinavica 115: 163–4.
HM Government (2007) Putting People First. A Shared Vision and Commitment to the Transformation of Adult Social Care. TSO (The Stationery Office).
Kay, S, Fiszbein, A, Opler, L (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13: 261–76.
Keith, S, Kane, J (2003) Partial compliance and patient consequences in schizophrenia: our patients can do better. Journal of Clinical Psychiatry 64: 1308–15.
Lambert, M, Naber, D, Schacht, A et al (2008a) Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatrica Scandinavica 118: 220–9.
Lambert, M, Martin, , Naber, D et al (2008b) Management of incomplete remission and treatment resistance in first-episode psychosis. Expert Opinion on Pharmacotherapy 9: 2039–51.
Lasser, RA, Bossie, CA, Gharabawi, GM et al (2005) Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophrenia Research 77: 215–27.
Leucht, S, Beitinger, R, Kissling, W (2007) On the concept of remission in schizophrenia. Psychopharmacology 194: 453–61.
Moncrieff, J (2007) The Myth of the Chemical Cure: A Critique of Psychiatric Drug Treatment. Palgrave Macmillan.
Mortimer, AM (2005) Another triumph of hope over experience? Revisiting: Treatment of the patient with long-term schizophrenia. Advances in Psychiatric Treatment 11: 277–85.
Mortimer, AM (2007) Symptom rating scales and outcome in schizophrenia. British Journal of Psychiatry 191 (suppl 50): s714.
Nasrallah, H, Dursun, SM (2006) Raising the bar for treatment expectations in schizophrenia: achieving remission as a routine goal of antipsychotic pharmacotherapy. Journal of Psychopharmacology 20 (suppl 6): 35.
Oyebode, F (2004) Invited commentary on: The rediscovery of recovery. Advances in Psychiatric Treatment 10: 48–9.
Peuskens, J, van Vleymen, B, Kaufman, L (2007) Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode. Schizophrenia Research 95: 169–73.
Priebe, S, Watzke, S, Hansson, L et al (2008) Objective social outcomes in mental health care. Acta Psychiatrica Scandinavica 118: 5763.
Roberts, G, Wolfson, P (2004) The rediscovery of recovery: open to all. Advances in Psychiatric Treatment 10: 3748.
Robinson, DG, Woerner, MG, McMeniman, M et al (2004) Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 161: 473–9.
Schrank, B, Slade, M (2007) Recovery in psychiatry. Psychiatric Bulletin 31: 321–5.
Schooler, NR, Hogarty, GE, Weissman, MM (1979) Social Adjustment Scale II (SAS). In Resource Materials for Community Health Program Evaluations (2nd edn) (Publication ADM 79–328) (eds Hargreaves, WP, Attkisson, CC, Sorenson, JE) 290302. US Department of Health, Education and Welfare.
Slade, M (2009) 100 Ways to Support Recovery. A Guide for Mental Health Professionals. Rethink (http://www.rethink.org/100ways).
van Os, J, Burns, T, Cavallaro, R et al (2006) Standardized remission criteria in schizophrenia. Acta Psychiatrica Scandinavica 113: 91–5.
Wunderink, L, Nienhuis, FJ, Sytema, S et al (2007) Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophrenia Bulletin 33: 792–6.